Abstract 82P
Background
Recent studies revealed contrasting prognostic roles of body-mass index (BMI) and tumor location in colorectal cancer (CRC). Given that right-sided and left-sided CRC may exhibit inverse impact on outcome and body weight, the present study is to examine whether the prognostic value of BMI and tumor location could be stratified reciprocally.
Methods
This prospective, observational study recruited 4,086 patients with diagnosed stage III CRC from 5 independent clinical centers in China. verall survival (OS) and disease-specific survival (DSS) was included as the clinical endpoints. The association of patients’ outcome with BMI and tumor location was evaluated hierarchically by Kaplan-Meier and Cox proportional-hazards model.
Results
Although BMI was not associated with outcome within total patients, this association was significantly modified by tumor location. Among left-sided tumors, obesity and overweight was significantly associated with adverse OS and DSS. In contrast, among right-sided tumors, overweight was significantly associated with more favorable OS and DSS compared with normal-weight group. The association of survival with tumor location did not reach statistical significance either. However, hierarchical analysis by BMI revealed that left-sided tumors were associated with more favorable outcome in normal-weight group, while no statistically significant difference in overweight or obese group.
Conclusions
BMI and tumor location may have opposing prognostic impact on CRC, stratified by each other, after adjusting for known prognostic factors. These findings are the first to show the interactive prognostic impact of BMI and tumor location, which could be relevant to stratification of patients' management.
Clinical trial identification
NCT02215642.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
490P - Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience
Presenter: Yvonne Ang
Session: Poster display session
Resources:
Abstract
498P - An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study
Presenter: Shang-gin Wu
Session: Poster display session
Resources:
Abstract
501P - Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
Presenter: Xin Gao
Session: Poster display session
Resources:
Abstract
502P - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
Presenter: Masaki Kanazu
Session: Poster display session
Resources:
Abstract
482P - Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo De Marinis
Session: Poster display session
Resources:
Abstract
483P - A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis
Presenter: Rafael Rosell
Session: Poster display session
Resources:
Abstract
484P - Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials
Presenter: Maya Gottfried
Session: Poster display session
Resources:
Abstract
491P - Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma
Presenter: Chia-I Shen
Session: Poster display session
Resources:
Abstract
510P - Paclitaxel as continuation maintenance therapy in patients with advanced non-small cell lung cancer
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract
496P - Higher osimertinib introduction rate achieved by multiple repeated re-biopsy after acquired resistance to first/second generation EGFR-TKIs
Presenter: Taira Ninomaru
Session: Poster display session
Resources:
Abstract